Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

Thorac Cancer. 2022 Dec;13(23):3420-3430. doi: 10.1111/1759-7714.14693. Epub 2022 Oct 21.

Abstract

Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.

Trial registration: ClinicalTrials.gov NCT05338619.

Keywords: Chinese experts consensus; checkpoint inhibitor pneumonitis; immune checkpoint inhibitor-related adverse effects.

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • China
  • Consensus
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Lung Neoplasms* / drug therapy
  • Pneumonia* / chemically induced
  • Pneumonia* / diagnosis
  • Pneumonia* / drug therapy

Substances

  • Immune Checkpoint Inhibitors
  • Antineoplastic Agents, Immunological

Associated data

  • ClinicalTrials.gov/NCT05338619